Tempest Reports Third Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics Q3 EPS $(0.21) Beats $(0.32) Estimate
Tempest Therapeutics Exercises Option to License Senlang’s CD7-Targeted Lentiviral In Vivo CAR-T Platform Following Initial Phase 1 Results with Lead BCMA/GPRC5D Candidate
Tempest Therapeutics Exercises Option To License Senlang’s CD7-Targeted Lentiviral Outside China
Tempest Therapeutics CFO Constance Ames Resigns; Co. Names Stephanie Horn-Warnock CFO, Treasurer, And Corporate Secretary, Effective Immediately.
Tempest Appoints John W. Frederick to Board of Directors, Strengthening Financial and Capital Markets Expertise
Tempest Therapeutics Files Prospectus Registering Resale Of Up To 9,534,164 Shares Of Common Stock
HC Wainwright & Co. Maintains Buy on Tempest Therapeutics, Lowers Price Target to $7
Tempest Appoints Global Finance Leader Nancy Freda-Smith to Board of Directors
Tempest Therapeutics (TPST) Stock Surges Wednesday: What's Driving the Action?
Tempest Therapeutics (TPST) Stock Climbs Over 66% After Hours: Here's Why
Tempest Secures Exclusive Option to License Clinical-Stage CD7-Targeted Lentiviral In Vivo CAR-T Platform
Tempest Therapeutics Announces Up to $7.5 Million Private Placement
Tempest Therapeutics Commences ~$2.5M Offering Of 3.106M Common Shares At $0.805 Per Share
Tempest to Present at the H.C. Wainwright 28th Annual Global Investment Conference
Tempest Therapeutics Says Justin Trojanowski To Resign As Principal Financial Officer Effective Sept 1; Nicholas Rossettos Appointed As CFO, Principal Financial Officer
Tempest Therapeutics Files Prospectus Related To The Offer And Sale Of Up To 8,910,579 Shares Of Common Stock
Tempest Reports Second Quarter 2026 Financial Results and Provides Business Update
Tempest Therapeutics Secures $50M Equity Purchase Agreement With Lincoln Park Capital
Tempest Therapeutics Q2 EPS $(0.34) Misses $(0.30) Estimate
Sign up for free to unlock this feature.
Creating your account...
Your account has been created. Redirecting...
Loading...
This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.